TLX-591 is a Monoclonal Antibody Conjugated owned by Telix Pharmaceuticals, and is involved in 12 clinical trials, of which 7 were completed, and 5 are ongoing.
TLX-591 combines the humanized J591 monoclonal antibody and Lutetium-177 radioisotope. J591 is a deimmunized monoclonal antibody (mAb), which specifically binds with high affinity to the extracellular domain of prostate-specific membrane antigen (PSMA). Lutetium-177, once internalized into the cell, is irreversibly sequestered within the targeted tumor cell. It emits radiation over a millimeter range that is ideal for eradication of the small volume lesions found in the bone marrow and lymph nodes.
The revenue for TLX-591 is expected to reach a total of $7.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the TLX-591 NPV Report.
TLX-591 is under development for the treatment of metastatic androgen-independent prostate cancer. The drug candidate is administered through intravenous infusion. ATL-101 is a (177) Lutetium radio-labelled J591 monoclonal antibody targeting prostate-specific membrane antigen (PSMA).
It was also under development for radio sensitive, kidney cancer, urothelium, head and neck, breast, non-small cell lung, colorectal, pancreatic cancer, ovarian cancer, esophageal and gliomas.
Telix Pharmaceuticals Overview
Telix Pharmaceuticals (Telix) is a biopharmaceutical company that develops and commercializes radiopharmaceuticals to detect and treat cancer. It offers Illuccix, an imaging agent targeting men with prostate cancer. The company is investigating TLX250-CDx (companion diagnostic) an imaging agent to diagnose renal cancer using positron emission tomography (PET); and TLX250, a radiopharmaceutical therapy against renal cancer. Telix is also evaluating TLX591, an antibody-based therapeutic radiopharmaceutical to treat prostate cancer; TLX101 drug for the treatment of glioblastoma (GBM); and TLX66-CDx and TLX66 programs for bone marrow conditioning. It utilizes molecularly-targeted radiation (MTR) technology, where a radionuclide is attached to a targeting small molecule or antibody that binds to tumor cells and destroys them. The company operates in the US, Japan, and Belgium. Telix is headquartered in Melbourne, Victoria, Australia.
The company reported revenues of (Australian Dollars) AUD7.6 million for the fiscal year ended December 2021 (FY2021), an increase of 45.7% over FY2020. The operating loss of the company was AUD75.3 million in FY2021, compared to an operating loss of AUD46.8 million in FY2020. The net loss of the company was AUD80.5 million in FY2021, compared to a net loss of AUD44.9 million in FY2020.
Quick View – TLX-591
|Highest Development Stage|